MediPharm Labs Corp. (TSX:LABS)
Canada · Delayed Price · Currency is CAD 0.0750
0.00 (0.00%)
Aug 10, 2026, 3:51 PM EST
MediPharm Labs Ratios and Metrics
Market cap in millions CAD. Fiscal year is January - December.
Millions CAD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 32 | 27 | 24 | 26 | 20 | 51 | |
Market Cap Growth | 8.78% | 11.08% | -6.17% | 32.09% | -60.97% | -38.62% |
Enterprise Value | 21.71 | 16.59 | 13.18 | 10.4 | -3.76 | 16.71 |
Last Close Price | 0.08 | 0.07 | 0.06 | 0.07 | 0.07 | 0.19 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Forward PE | - | 22.71 | 22.71 | 22.71 | 22.71 | 22.71 |
PS Ratio | 0.74 | 0.60 | 0.58 | 0.79 | 0.89 | 2.33 |
PB Ratio | 0.91 | 0.76 | 0.57 | 0.49 | 0.35 | 0.61 |
P/TBV Ratio | 0.92 | 0.77 | 0.58 | 0.45 | 0.35 | 0.56 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 0.50 | 0.37 | 0.31 | 0.31 | -0.17 | 0.77 |
EV/EBITDA Ratio | - | - | - | - | 0.14 | - |
EV/EBIT Ratio | - | - | - | - | 0.13 | - |
EV/FCF Ratio | - | - | - | - | 0.22 | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.00 | 0.01 | 0.01 | 0.04 | 0.01 | 0.00 |
Net Debt / Equity Ratio | -0.28 | -0.30 | -0.26 | -0.30 | -0.42 | -0.41 |
Net Debt / EBITDA Ratio | 1.35 | 1.57 | 1.38 | 1.00 | 0.88 | 0.78 |
Net Debt / FCF Ratio | 2.92 | 1.89 | 2.25 | 1.23 | 1.39 | 2.42 |
Asset Turnover | 0.97 | 0.91 | 0.71 | 0.51 | 0.28 | 0.21 |
Inventory Turnover | 3.69 | 3.77 | 3.06 | 3.21 | 2.56 | 2.23 |
Quick Ratio | 1.92 | 1.85 | 1.83 | 2.20 | 3.92 | 5.75 |
Current Ratio | 3.02 | 2.77 | 3.15 | 3.37 | 9.93 | 7.38 |
Return on Equity (ROE) | -24.67% | -20.93% | -22.24% | -24.00% | -43.09% | -67.84% |
Return on Assets (ROA) | -19.94% | -16.96% | -18.37% | -28.79% | -37.43% | -46.36% |
Return on Invested Capital (ROIC) | -35.31% | -29.55% | -31.24% | -53.37% | -72.27% | -77.17% |
Return on Capital Employed (ROCE) | -25.12% | -21.34% | -22.45% | -33.46% | -42.33% | -55.13% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Buyback Yield / Dilution | -2.41% | -2.53% | -12.29% | -31.23% | -10.79% | -80.37% |
Total Shareholder Return | -2.41% | -2.53% | -12.29% | -31.23% | -10.79% | -80.37% |